RL
Richard E Lowenthal
President and CEO

Richard E Lowenthal insider trades: ARS Pharmaceuticals (SPRY) stock sales

President and CEO, ARS Pharmaceuticals Last trade Aug 21, 2025 32 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
47
Open-market trades
since 2024
2
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Richard reports to the SEC

Open-market buys and sales

47 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 21, 2025SPRY↓ Sell10b5-1$724K
Dec 17, 2024SPRY↓ Sell10b5-1$584K
Dec 17, 2024SPRY↓ Sell10b5-1$584K
Dec 10, 2024SPRY↓ Sell10b5-1$658K
Dec 10, 2024SPRY↓ Sell10b5-1$658K
Nov 19, 2024SPRY↓ Sell10b5-1$698K
Nov 19, 2024SPRY↓ Sell10b5-1$697K
Nov 12, 2024SPRY↓ Sell10b5-1$842K
Nov 12, 2024SPRY↓ Sell10b5-1$842K
Oct 15, 2024SPRY↓ Sell10b5-1$744K
Oct 15, 2024SPRY↓ Sell10b5-1$744K
Oct 8, 2024SPRY↓ Sell10b5-1$691K
Oct 8, 2024SPRY↓ Sell10b5-1$691K
Sep 17, 2024SPRY↓ Sell10b5-1$647K
Sep 17, 2024SPRY↓ Sell10b5-1$647K
Sep 10, 2024SPRY↓ Sell10b5-1$575K
Sep 10, 2024SPRY↓ Sell10b5-1$575K
Aug 20, 2024SPRY↓ Sell10b5-1$751K
Aug 20, 2024SPRY↓ Sell10b5-1$751K
Aug 13, 2024SPRY↓ Sell10b5-1$624K
Aug 13, 2024SPRY↓ Sell10b5-1$624K
Jul 16, 2024SPRY↓ Sell10b5-1$570K
Jul 16, 2024SPRY↓ Sell10b5-1$570K
Jul 9, 2024SPRY↓ Sell10b5-1$481K
Jul 9, 2024SPRY↓ Sell10b5-1$481K
Jun 12, 2024SPRY↓ Sell10b5-1$457K
Jun 12, 2024SPRY↓ Sell10b5-1$457K
May 16, 2024SPRY↓ Sell10b5-1$453K
May 16, 2024SPRY↓ Sell10b5-1$453K
May 7, 2024SPRY↓ Sell10b5-1$467K
May 7, 2024SPRY↓ Sell10b5-1$467K
Apr 16, 2024SPRY↓ Sell10b5-1$464K
Apr 16, 2024SPRY↓ Sell10b5-1$464K
Apr 9, 2024SPRY↓ Sell10b5-1$464K
Apr 9, 2024SPRY↓ Sell10b5-1$464K
Mar 25, 2024SPRY↓ Sell10b5-1$447K
Mar 25, 2024SPRY↓ Sell10b5-1$444K
Mar 21, 2024SPRY↓ Sell10b5-1$12K
Mar 21, 2024SPRY↓ Sell10b5-1$9K
Mar 15, 2024SPRY↓ Sell10b5-1$457K
Mar 15, 2024SPRY↓ Sell10b5-1$457K
Feb 29, 2024SPRY↓ Sell10b5-1$18K
Feb 29, 2024SPRY↓ Sell10b5-1$9K
Feb 29, 2024SPRY↓ Sell10b5-1$7K
Feb 28, 2024SPRY↓ Sell10b5-1$447K
Feb 28, 2024SPRY↓ Sell10b5-1$231K
Feb 28, 2024SPRY↓ Sell10b5-1$220K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other SPRY insiders

Open-market trades in the last 12 months

About Richard E Lowenthal's insider trades

Richard E Lowenthal is President and CEO at ARS Pharmaceuticals (SPRY). Since Feb 28, 2024, Richard has reported no open-market purchases and 47 sales worth $23.8M on SEC Form 4. There have been no open-market trades in the last 12 months.

47 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (6 filings), option exercises (3 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SPRY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.